Hexagon Nutrition H1 revenue rose 27.3% as margins fell
Key highlights
- Hexagon Nutrition reported H1 FY27 revenue of Rs 213.967 crore, up 27.33% year on year.
- H1 FY27 EBITDA was Rs 22.661 crore, while EBITDA margin fell to 10.59% from 13.27%.
- Q2 FY27 PAT declined to Rs 8.165 crore from Rs 10.137 crore in Q2 FY26.
- H1 FY27 Premix value growth was 51.4%, compared with 25.5% for the Brand segment.
powered by IRIS

Hexagon Nutrition Limited reported H1 FY27 revenue growth of 27.3% to Rs 213.967 crore, but its earnings before interest, tax, depreciation and amortisation (EBITDA) margin declined to 10.59% from 13.27% a year earlier. Profit after tax (PAT) was Rs 16.238 crore, below Rs 16.592 crore in H1 FY26 despite higher sales.
Know Hexagon Nutrition inside out
Results, valuation, peers and who's buying, in one view.
What did Hexagon Nutrition report for H1 FY27?
Hexagon Nutrition reported H1 FY27 revenue from operations of Rs 213.967 crore, up from Rs 168.045 crore in H1 FY26, while EBITDA increased 1.61% to Rs 22.661 crore. Revenue expanded 27.33%, but EBITDA rose by Rs 0.360 crore, resulting in a 2.68-percentage-point decline in EBITDA margin to 10.59%.
PAT was Rs 16.238 crore in H1 FY27, compared with Rs 16.592 crore in H1 FY26, while PAT margin declined to 7.59% from 9.87%. Profit before tax (PBT) was Rs 20.750 crore, down from Rs 21.808 crore. The reported half-year figures therefore show revenue growth alongside lower PBT and PAT than in the corresponding FY26 period.
Why did Hexagon Nutrition's H1 margin decline?
Hexagon Nutrition's profit and loss statement shows expenses increasing alongside revenue, but it does not attribute the margin movement to a single expense category. H1 FY27 total expenses were Rs 196.951 crore, versus Rs 151.972 crore in H1 FY26, while total income rose to Rs 218.772 crore from Rs 173.743 crore. Management said margins moderated compared with the previous year and named operational efficiency and profitability improvement as focus areas.
Cost of materials consumed increased to Rs 137.447 crore in H1 FY27 from Rs 85.628 crore in H1 FY26, while employee-benefit expense rose to Rs 29.754 crore from Rs 23.795 crore. Other expenses increased to Rs 43.891 crore from Rs 38.621 crore. Changes in finished-goods and work-in-progress inventories were negative Rs 22.112 crore, compared with negative Rs 6.089 crore a year earlier, although the presentation does not quantify each line item's impact on margin.
How did Hexagon Nutrition perform in Q2 FY27?
Hexagon Nutrition delivered Q2 FY27 revenue of Rs 109.661 crore, a 15.21% year-on-year increase from Rs 95.184 crore, but EBITDA declined 11.28% to Rs 10.860 crore. Q2 EBITDA margin was 9.90%, down from 12.86% in Q2 FY26 and below the 10.59% margin recorded for H1 FY27.
Q2 FY27 PAT was Rs 8.165 crore, compared with Rs 10.137 crore in Q2 FY26, consistent with the presentation's reported 19% year-on-year PAT decline. PAT margin fell to 7.45% from 10.65%, while PBT declined 23.90% to Rs 10.149 crore. Finance costs were Rs 1.021 crore, compared with Rs 0.988 crore, and depreciation and amortisation was Rs 2.417 crore against Rs 2.238 crore.
Got a follow-up? Ask IRIS
Which Hexagon Nutrition segments drove H1 FY27 growth?
Hexagon Nutrition's Premix segment was the faster-growing reported business in H1 FY27, with value growth of 51.4% year on year, compared with 25.5% for the Brand segment. Total value growth was 27.3%, meaning Premix growth exceeded Brand growth by 25.9 percentage points.
In Q2 FY27, Premix value growth was 47.7%, while Brand growth was 29.0% and total growth was 15.2%. In Q1 FY27, Premix grew 55.4%, Brand grew 21.2%, and total growth was 43.0%. The presentation does not disclose segment revenue in rupees or segment profitability, so it does not establish either segment's contribution to H1 EBITDA margin of 10.59%.
What is Hexagon Nutrition planning after H1 FY27?
Hexagon Nutrition says it is focused on expanding its international presence, strengthening domestic distribution and developing high-value nutrition solutions across Micronutrient Premixes, Clinical Nutrition and Therapeutic Nutrition. Management also cited stronger operational capabilities, improved capacity utilisation and greater efficiencies as mechanisms for pursuing profitable growth. The presentation does not provide a quantified FY27 revenue, EBITDA-margin or capacity-utilisation target.
The balance sheet recorded inventory of Rs 136.145 crore at H1 FY27, compared with Rs 83.901 crore at FY26, while trade receivables reduced to Rs 76.645 crore from Rs 81.718 crore. Short-term borrowings increased to Rs 32.739 crore from Rs 24.496 crore, and trade payables rose to Rs 47.270 crore from Rs 28.792 crore. These are reported balance-sheet changes rather than management's stated explanation for the H1 margin outcome.
Conclusion
Hexagon Nutrition's H1 FY27 results combine 27.3% revenue growth with EBITDA margin declining to 10.59% and PAT falling to Rs 16.238 crore from Rs 16.592 crore in H1 FY26. Premix value growth of 51.4% and Brand growth of 25.5% indicate expansion across both reported businesses, but the increase in revenue did not translate into proportionate EBITDA growth.
The next reported results will indicate whether management's plans for operational efficiency, capacity utilisation, international expansion, domestic distribution and high-value products affect profitability. Points to watch include whether EBITDA margin recovers from Q2 FY27's 9.90% and whether Q2 Premix growth of 47.7% and Brand growth of 29.0% continue without a further decline in PAT margin.


